Evidence map›Paper›PMID 33941588›Full record

ArticleJournal of clinical pathology2022

Expression of p16

Ewelina Bartkowiak, Krzysztof Piwowarczyk, Magdalena Bodnar, Paweł Kosikowski, Jadzia Chou, Aldona Woźniak, Małgorzata Wierzbicka

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ewelina BartkowiakDepartment of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznan, Poland ewelina.anna.bartkowiak@gmail.com.ORCID http://orcid.org/0000-0003-3351-0923
Krzysztof PiwowarczykDepartment of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Magdalena BodnarDepartment of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Paweł KosikowskiDepartment of Clinical Pathology, Poznan University of Medical Sciences, Poznan, Poland.
Jadzia ChouDepartment of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Aldona WoźniakDepartment of Clinical Pathology, Poznan University of Medical Sciences, Poznan, Poland.
Małgorzata WierzbickaDepartment of Otolaryngology and Laryngological Oncology, Poznan University of Medical Sciences, Poznan, Poland.
Poznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aim of the study is to correlate p16

methodsRetrospective analysis (1998-2019) of 47 CaexPA, 148 PA and 22 normal salivary gland samples was performed. PAs were divided into two subsets: clinically 'slow' tumours characterised by stable size or slow growth; and 'fast' tumours with rapid growth rate.

resultsPositive p16

conclusionsOur study confirms no p16

Indexed as

AdenocarcinomaAdenoma, PleomorphicSalivary Gland NeoplasmsBiologyCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p16HumansImmunohistochemistryRetrospective StudiesCyclin-Dependent Kinase Inhibitor p16adenomahead and neck neoplasmsimmunohistochemistrymicroarray analysispleomorphicsalivary glands

Identifiers

PMID33941588
PMCPMC9411887
OpenAlexW3158917837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.